Citadel Advisors
EVFM

Citadel Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Citadel Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-210,122
Closed -$238K – 14305
2022
Q2 		$238K Buy
210,122
+189,524
+920% +$313K ﹤0.01% 10327
2022
Q1 		$105K Buy
20,598
+18,733
+1,004% +$118K ﹤0.01% 12246
2021
Q4 		$11K Sell
1,865
-7,161
-79% -$60.9K ﹤0.01% 13666
2021
Q3 		$100K Sell
9,026
-2,482
-22% -$31.2K ﹤0.01% 12875
2021
Q2 		$195K Buy
11,508
+9,458
+461% +$179K ﹤0.01% 12190
2021
Q1 		$54K Buy
+2,050
New +$93.2K ﹤0.01% 12873
2020
Q4 		– Sell
-3,026
Closed -$109K – 11759
2020
Q3 		$107K Buy
3,026
+512
+20% +$22.3K ﹤0.01% 9238
2020
Q2 		$107K Buy
2,514
+1,084
+76% +$73.1K ﹤0.01% 8957
2020
Q1 		$114K Buy
+1,430
New +$114K ﹤0.01% 8544
2017
Q3 		– Sell
-363
Closed -$18K – 8249
2017
Q2 		$18K Buy
363
+206
+131% +$36.1K ﹤0.01% 7309
2017
Q1 		$23K Buy
+157
New +$20.4K ﹤0.01% 7220
2016
Q4 		– Sell
-164
Closed -$17K – 8063
2016
Q3 		$17K Buy
+164
New +$15K ﹤0.01% 7097

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Citadel Advisors's EVFM Position: Q3 2022 in Review

Citadel Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 210,122 shares — an estimated $238K sold.

Citadel Advisors first reported a position in EVFM in Q3 2016 and held it in 12 quarters. The position peaked at $238K in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Citadel Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 210,122 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $238K.
  • Citadel Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2016 and held it in 12 quarters.
  • Citadel Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $238K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.